262 related articles for article (PubMed ID: 37505499)
61. BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Carcinoma in Chinese Patients.
Sun J; Zhang J; Lu J; Gao J; Ren X; Teng L; Duan H; Lin Y; Li X; Zhang B; Liang Z
PLoS One; 2016; 11(4):e0153319. PubMed ID: 27064992
[TBL] [Abstract][Full Text] [Related]
62. Analysis of BRAF(V600E) mutation and DNA methylation improves the diagnostics of thyroid fine needle aspiration biopsies.
Zhang B; Liu S; Zhang Z; Wei J; Qu Y; Wu K; Yang Q; Hou P; Shi B
Diagn Pathol; 2014 Mar; 9():45. PubMed ID: 24588959
[TBL] [Abstract][Full Text] [Related]
63. Effect of BRAF V600E mutation detection of fine-needle aspiration biopsy on diagnosis and treatment guidance of papillary thyroid carcinoma.
Qi W; Shi C; Zhang P; Feng L; Wang J; Chen D
Pathol Res Pract; 2020 Aug; 216(8):153037. PubMed ID: 32703500
[TBL] [Abstract][Full Text] [Related]
64. [The value of multi-gene testing in benign or malign diagnosis of thyroid nodules with indeterminate cytology].
Song YT; Xu GH; Zhu YL; Ma TH; Yu H; Wang TX; Yu WB; Wei W; Zhang B
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2019 Oct; 54(10):764-768. PubMed ID: 31606990
[No Abstract] [Full Text] [Related]
65. Molecular testing of BRAF, RAS and TERT on thyroid FNAs with indeterminate cytology improves diagnostic accuracy.
Decaussin-Petrucci M; Descotes F; Depaepe L; Lapras V; Denier ML; Borson-Chazot F; Lifante JC; Lopez J
Cytopathology; 2017 Dec; 28(6):482-487. PubMed ID: 29094776
[TBL] [Abstract][Full Text] [Related]
66. Highly prevalent TERT promoter mutations in aggressive thyroid cancers.
Liu X; Bishop J; Shan Y; Pai S; Liu D; Murugan AK; Sun H; El-Naggar AK; Xing M
Endocr Relat Cancer; 2013 Aug; 20(4):603-10. PubMed ID: 23766237
[TBL] [Abstract][Full Text] [Related]
67. TERT promoter mutations in thyroid cancer.
Liu R; Xing M
Endocr Relat Cancer; 2016 Mar; 23(3):R143-55. PubMed ID: 26733501
[TBL] [Abstract][Full Text] [Related]
68. Presence of TERT ± BRAF V600E mutation is not a risk factor for the clinical management of patients with papillary thyroid microcarcinoma.
Lee J; Ha EJ; Roh J; Kim HK
Surgery; 2021 Sep; 170(3):743-747. PubMed ID: 33952391
[TBL] [Abstract][Full Text] [Related]
69. Diagnostic value of BRAF(V600E) mutation analysis of thyroid nodules according to ultrasonographic features and the time of aspiration.
Moon HJ; Kim EK; Chung WY; Choi JR; Yoon JH; Kwak JY
Ann Surg Oncol; 2011 Mar; 18(3):792-9. PubMed ID: 20945104
[TBL] [Abstract][Full Text] [Related]
70. BRAF and TERT promoter mutations in the aggressiveness of papillary thyroid carcinoma: a study of 653 patients.
Jin L; Chen E; Dong S; Cai Y; Zhang X; Zhou Y; Zeng R; Yang F; Pan C; Liu Y; Wu W; Xing M; Zhang X; Wang O
Oncotarget; 2016 Apr; 7(14):18346-55. PubMed ID: 26943032
[TBL] [Abstract][Full Text] [Related]
71. Proper indication of BRAF(V600E) mutation testing in fine-needle aspirates of thyroid nodules.
Koh J; Choi JR; Han KH; Kim EK; Yoon JH; Moon HJ; Kwak JY
PLoS One; 2013; 8(5):e64505. PubMed ID: 23717622
[TBL] [Abstract][Full Text] [Related]
72. BRAF mutation analysis by ARMS-PCR refines thyroid nodule management.
Li X; Li E; Du J; Wang J; Zheng B
Clin Endocrinol (Oxf); 2019 Dec; 91(6):834-841. PubMed ID: 31441082
[TBL] [Abstract][Full Text] [Related]
73. Prognostic effects of TERT promoter mutations are enhanced by coexistence with BRAF or RAS mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients.
Song YS; Lim JA; Choi H; Won JK; Moon JH; Cho SW; Lee KE; Park YJ; Yi KH; Park DJ; Seo JS
Cancer; 2016 May; 122(9):1370-9. PubMed ID: 26969876
[TBL] [Abstract][Full Text] [Related]
74. The combination of four molecular markers improves thyroid cancer cytologic diagnosis and patient management.
Panebianco F; Mazzanti C; Tomei S; Aretini P; Franceschi S; Lessi F; Di Coscio G; Bevilacqua G; Marchetti I
BMC Cancer; 2015 Nov; 15():918. PubMed ID: 26581891
[TBL] [Abstract][Full Text] [Related]
75. Evaluation of the Molecular Landscape of Pediatric Thyroid Nodules and Use of a Multigene Genomic Classifier in Children.
Gallant JN; Chen SC; Ortega CA; Rohde SL; Belcher RH; Netterville JL; Baregamian N; Wang H; Liang J; Ye F; Nikiforov YE; Nikiforova MN; Weiss VL
JAMA Oncol; 2022 Sep; 8(9):1323-1327. PubMed ID: 35679040
[TBL] [Abstract][Full Text] [Related]
76. [Diagnostic values of BRAF(V600E) mutation analysis and Bethesda system for reporting thyroid cytopathology in thyroid nodules with TIRADS 4 and 5].
Han Y; Zhao BW; Li SY; Lyu JG; Shou JD; Xu HS; Lou HY; Xu LL; Gao L; Xu SX; Zhu J
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2017 Sep; 52(9):686-691. PubMed ID: 28910894
[No Abstract] [Full Text] [Related]
77. Multiple Mutations Detected Preoperatively May Predict Aggressive Behavior of Papillary Thyroid Cancer and Guide Management--A Case Report.
Shrestha RT; Karunamurthy A; Amin K; Nikiforov YE; Caramori ML
Thyroid; 2015 Dec; 25(12):1375-8. PubMed ID: 26355276
[TBL] [Abstract][Full Text] [Related]
78. Malignant risk stratification of thyroid FNA specimens with indeterminate cytology based on molecular testing.
Paskaš S; Janković J; Živaljević V; Tatić S; Božić V; Nikolić A; Radojković D; Savin S; Cvejić D
Cancer Cytopathol; 2015 Aug; 123(8):471-9. PubMed ID: 25924719
[TBL] [Abstract][Full Text] [Related]
79. Detection of driver mutations in plasma cell-free nucleic acids in differentiated thyroid neoplasm.
Dutta S; Tarafdar S; Mukhopadhyay P; Bhattacharyya NP; Ghosh S
Eur J Endocrinol; 2023 Jan; 188(1):. PubMed ID: 36744987
[TBL] [Abstract][Full Text] [Related]
80. Diagnostic value of B-RAF(V600E) in difficult-to-diagnose thyroid nodules using fine-needle aspiration: systematic review and meta-analysis.
Jia Y; Yu Y; Li X; Wei S; Zheng X; Yang X; Zhao J; Xia T; Gao M
Diagn Cytopathol; 2014 Jan; 42(1):94-101. PubMed ID: 24167125
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
